Literature DB >> 30294537

Evaluation of Glypican-3 expression in benign and malignant salivary gland tumors.

Azadeh Andisheh-Tadbir1, Mohammad Javad Ashraf2, Ali Gudarzi3, Razieh Zare4.   

Abstract

INTRODUCTION: Glypican-3 (GPC3) is involved in regulation of cell proliferation and morphogenesis. It is abundant in embryonic tissue, but limited in most adult tissues. GPC3 deletion or mutation can disturb the balance between cell apoptosis and proliferation, which may result in tumorigenesis. This study aimed to investigate the GPC3 expression in salivary gland tumors (SGTs) and the adjacent non-neoplastic tissues.
METHODS: This study reviewed 50 samples of salivary tumors from the archive of Khalili Hospital, Shiraz, Iran, including 17 cases of pleomorphic adenoma (PA), 16 cases of mucoepidermoid carcinoma (MEC), and 17 cases of adenoid cystic carcinoma (ACC); as well as a control group of 23 cases of normal salivary gland tissues. GPC3 expression was investigated through immunohistochemistry.
RESULTS: GPC3 expression was significantly higher in malignant tumors (MEC and ACC) than in PA, and higher in PA than in the normal salivary glands (P < 0.001). The expression intensity was moderate to strong in malignant tumors and weak to moderate in benign tumors. No strong positivity was observed in normal salivary gland tissues (P < 0.001). Nor was any association detected between the GPC3 expression and intensity with the clinicopathologic parameters.
CONCLUSION: Although GPC3 overexpression was observed at the protein level in SGTs, and its expression was not related with the clinicopathologic factors, the potential use of GPC3 for diagnostic, therapeutic, and prognostic purposes requires further investigations.

Entities:  

Keywords:  ACC; GPC3; MEC; PA; Salivary gland tumor

Year:  2018        PMID: 30294537      PMCID: PMC6170252          DOI: 10.1016/j.jobcr.2018.09.002

Source DB:  PubMed          Journal:  J Oral Biol Craniofac Res        ISSN: 2212-4268


  26 in total

1.  The oncofetal protein glypican-3 is a novel marker of hepatic progenitor/oval cells.

Authors:  Petar N Grozdanov; Mladen I Yovchev; Mariana D Dabeva
Journal:  Lab Invest       Date:  2006-10-02       Impact factor: 5.662

2.  Highly sensitive detection of melanoma at an early stage based on the increased serum secreted protein acidic and rich in cysteine and glypican-3 levels.

Authors:  Yoshiaki Ikuta; Tetsuya Nakatsura; Toshiro Kageshita; Satoshi Fukushima; Shosuke Ito; Kazumasa Wakamatsu; Hideo Baba; Yasuharu Nishimura
Journal:  Clin Cancer Res       Date:  2005-11-15       Impact factor: 12.531

3.  Cloning and expression of a developmentally regulated transcript MXR7 in hepatocellular carcinoma: biological significance and temporospatial distribution.

Authors:  H C Hsu; W Cheng; P L Lai
Journal:  Cancer Res       Date:  1997-11-15       Impact factor: 12.701

Review 4.  TNM staging of cancers of the head and neck: striving for uniformity among diversity.

Authors:  Snehal G Patel; Jatin P Shah
Journal:  CA Cancer J Clin       Date:  2005 Jul-Aug       Impact factor: 508.702

5.  Glypican-3 expression is silenced in human breast cancer.

Authors:  Y Y Xiang; V Ladeda; J Filmus
Journal:  Oncogene       Date:  2001-11-01       Impact factor: 9.867

6.  Relation of glypican-3 and E-cadherin expressions to clinicopathological features and prognosis of mucinous and non-mucinous colorectal adenocarcinoma.

Authors:  Abd Al-Rahman Mohammad Foda; Mie Ali Mohammad; Azza Abdel-Aziz; Amira Kamal El-Hawary
Journal:  Tumour Biol       Date:  2015-01-27

7.  Salivary gland tumors: a clinicopathologic study of 366 cases in southern Iran.

Authors:  Zohreh Jaafari-Ashkavandi; Mohammad-Javad Ashraf; Maryam Moshaverinia
Journal:  Asian Pac J Cancer Prev       Date:  2013

8.  Identification of glypican-3 as a novel tumor marker for melanoma.

Authors:  Tetsuya Nakatsura; Toshiro Kageshita; Shosuke Ito; Kazumasa Wakamatsu; Mikio Monji; Yoshiaki Ikuta; Satoru Senju; Tomomichi Ono; Yasuharu Nishimura
Journal:  Clin Cancer Res       Date:  2004-10-01       Impact factor: 12.531

9.  Human homolog of NOTUM, overexpressed in hepatocellular carcinoma, is regulated transcriptionally by beta-catenin/TCF.

Authors:  Yuichi Torisu; Akira Watanabe; Aya Nonaka; Yutaka Midorikawa; Masatoshi Makuuchi; Takahiro Shimamura; Haruhiko Sugimura; Atsushi Niida; Tetsu Akiyama; Hiroko Iwanari; Tatsuhiko Kodama; Mikio Zeniya; Hiroyuki Aburatani
Journal:  Cancer Sci       Date:  2008-04-21       Impact factor: 6.716

10.  GPC3 reduces cell proliferation in renal carcinoma cell lines.

Authors:  Marina Curado Valsechi; Ana Beatriz Bortolozo Oliveira; André Luis Giacometti Conceição; Bruna Stuqui; Natalia Maria Candido; Paola Jocelan Scarin Provazzi; Luiza Ferreira de Araújo; Wilson Araújo Silva; Marilia de Freitas Calmon; Paula Rahal
Journal:  BMC Cancer       Date:  2014-08-29       Impact factor: 4.430

View more
  2 in total

Review 1.  The Role of Glypicans in Cancer Progression and Therapy.

Authors:  Nan Li; Madeline R Spetz; Mitchell Ho
Journal:  J Histochem Cytochem       Date:  2020-07-06       Impact factor: 2.479

2.  Glypican-3 Expression in Patients with Oral Squamous Cell Carcinoma.

Authors:  Azadeh Andisheh-Tadbir; Amir Saeed Goharian; Mohammad Ali Ranjbar
Journal:  J Dent (Shiraz)       Date:  2020-06
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.